Organogenesis Holdings Inc. (ORGO): Price and Financial Metrics


Organogenesis Holdings Inc. (ORGO): $2.80

-0.13 (-4.44%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ORGO to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ORGO POWR Grades

  • Value is the dimension where ORGO ranks best; there it ranks ahead of 99.78% of US stocks.
  • The strongest trend for ORGO is in Stability, which has been heading up over the past 177 days.
  • ORGO ranks lowest in Growth; there it ranks in the 8th percentile.

ORGO Stock Summary

  • With a price/earnings ratio of 6.32, ORGANOGENESIS HOLDINGS INC P/E ratio is greater than that of about merely 14.34% of stocks in our set with positive earnings.
  • In terms of twelve month growth in earnings before interest and taxes, ORGANOGENESIS HOLDINGS INC is reporting a growth rate of -51.62%; that's higher than just 23.14% of US stocks.
  • In terms of volatility of its share price, ORGO is more volatile than 86.78% of stocks we're observing.
  • Stocks that are quantitatively similar to ORGO, based on their financial statements, market capitalization, and price volatility, are JOUT, BRC, IOSP, MGIC, and EML.
  • ORGO's SEC filings can be seen here. And to visit ORGANOGENESIS HOLDINGS INC's official web site, go to organogenesis.com.

ORGO Valuation Summary

  • ORGO's price/sales ratio is 0.7; this is 66.67% lower than that of the median Healthcare stock.
  • Over the past 74 months, ORGO's EV/EBIT ratio has gone NA NA.

Below are key valuation metrics over time for ORGO.

Stock Date P/S P/B P/E EV/EBIT
ORGO 2023-01-30 0.7 1.3 5.3 9.8
ORGO 2023-01-27 0.7 1.3 5.6 10.3
ORGO 2023-01-26 0.7 1.3 5.5 10.1
ORGO 2023-01-25 0.7 1.3 5.3 9.8
ORGO 2023-01-24 0.7 1.3 5.6 10.2
ORGO 2023-01-23 0.7 1.3 5.5 10.1

ORGO Growth Metrics

    Its 5 year net income to common stockholders growth rate is now at -19903.07%.
  • The 3 year net income to common stockholders growth rate now stands at 205.83%.
  • The 4 year net cashflow from operations growth rate now stands at -7237.35%.
Over the past 33 months, ORGO's revenue has gone up $203,954,000.

The table below shows ORGO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 464.935 35.007 60.741
2022-06-30 461.829 57.404 73.103
2022-03-31 463.624 64.868 85.046
2021-12-31 468.059 61.978 94.902
2021-09-30 446.308 70.306 61.701
2021-06-30 433.354 49.599 70.058

ORGO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ORGO has a Quality Grade of B, ranking ahead of 77.36% of graded US stocks.
  • ORGO's asset turnover comes in at 1.426 -- ranking 12th of 681 Pharmaceutical Products stocks.
  • VRTX, ACOR, and TPST are the stocks whose asset turnover ratios are most correlated with ORGO.

The table below shows ORGO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 1.426 0.760 0.406
2021-03-31 1.409 0.752 0.298
2020-12-31 1.401 0.742 0.166
2020-09-30 1.373 0.732 0.035
2020-06-30 1.315 0.709 -0.159
2020-03-31 1.377 0.707 -0.204

ORGO Price Target

For more insight on analysts targets of ORGO, see our ORGO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $26.75 Average Broker Recommendation 1.12 (Strong Buy)

ORGO Stock Price Chart Interactive Chart >

Price chart for ORGO

ORGO Price/Volume Stats

Current price $2.80 52-week high $9.27
Prev. close $2.93 52-week low $2.23
Day low $2.77 Volume 622,692
Day high $2.92 Avg. volume 656,243
50-day MA $2.65 Dividend yield N/A
200-day MA $4.11 Market Cap 366.56M

Organogenesis Holdings Inc. (ORGO) Company Bio


Organogenesis Holdings Inc. operates as a holding company. The Company, through its subsidiaries, focuses on development, manufacturing, and commercializing drugs and medicines for wound care, surgical, and sports medicine markets. Organogenesis Holdings serves customers in the United States and Switzerland.


ORGO Latest News Stream


Event/Time News Detail
Loading, please wait...

ORGO Latest Social Stream


Loading social stream, please wait...

View Full ORGO Social Stream

Latest ORGO News From Around the Web

Below are the latest news stories about ORGANOGENESIS HOLDINGS INC that investors may wish to consider to help them evaluate ORGO as an investment opportunity.

Have you been able to find a good deal on Organogenesis Holdings Inc.’s shares?

The share price of Organogenesis Holdings Inc. (NASDAQ:ORGO) fell to $2.48 per share on Wednesday from $2.58. While Organogenesis Holdings Inc. has underperformed by -3.88%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ORGO fell by -67.07%, with highs and lows ranging from $9.27 to $2.23, […]

US Post News | January 26, 2023

How should investors view Organogenesis Holdings Inc. (ORGO)?

Organogenesis Holdings Inc. (NASDAQ:ORGO) marked $2.59 per share on Friday, down from a previous closing price of $2.90. While Organogenesis Holdings Inc. has underperformed by -10.69%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ORGO fell by -69.09%, with highs and lows ranging from $9.27 to […]

US Post News | January 16, 2023

Results from Organogenesis Holdings Inc. (ORGO) show potential

Organogenesis Holdings Inc. (NASDAQ:ORGO) marked $2.61 per share on Wednesday, up from a previous closing price of $2.51. While Organogenesis Holdings Inc. has overperformed by 3.98%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ORGO fell by -72.84%, with highs and lows ranging from $10.39 to […]

US Post News | December 22, 2022

Organogenesis Holdings Inc. to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech Conference

CANTON, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that company management will participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech Conference, which is being held at The Fontainebleau Miami Beach in Mi

Yahoo | December 5, 2022

Lifshitz Law PLLC Announces Investigations of Sleep Number Corporation (NASDAQ: SNBR), Organogenesis Holdings, Inc. (NASDAQ: ORGO), Netflix Inc. (NASDAQ: NFLX), and Mullen Automotive Inc. (NASDAQ: MULN)

NEW YORK, Nov. 19, 2022 (GLOBE NEWSWIRE) -- Sleep Number Corporation (NASDAQ: SNBR)

GlobeNewswire | November 19, 2022

Read More 'ORGO' Stories Here

ORGO Price Returns

1-mo 3.70%
3-mo -11.67%
6-mo -54.77%
1-year -60.34%
3-year -39.66%
5-year -72.11%
YTD 4.09%
2022 -70.89%
2021 22.71%
2020 56.55%
2019 N/A
2018 0.00%

Continue Researching ORGO

Want to see what other sources are saying about Organogenesis Holdings Inc's financials and stock price? Try the links below:

Organogenesis Holdings Inc (ORGO) Stock Price | Nasdaq
Organogenesis Holdings Inc (ORGO) Stock Quote, History and News - Yahoo Finance
Organogenesis Holdings Inc (ORGO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7749 seconds.